GGrantIndex
← Leaderboards

Yu-Long Li

University Of Nebraska Medical Center

$10,009,035
Attributed
$10,881,508
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY201025
$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,881,508 · 6

By mechanism

R01$10,881,508 · 6

Top collaborators

Most similar at University Of Nebraska Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Nerve

Research focus

NerveAnimalsMediatingSignal PathwayIn VitroFunctional DisorderDesignIn VivoMolecularSignal TransductionCellsRattusNeuronsTransfectionLinkTissuesCardiacProductionMortalityAffectConsciousMyocardial InfarctionInflammatoryTnf Gene

Grant awards (24)

Mechanisms of cardiac sympathetic hyperactivity in chronic heart failure$645,067
R01 · FY2025 · HL · contact PI
Potential mechanism underlying parasympathetic neuronal dysfunction in diabetes$603,326
R01 · FY2025 · HL · contact PI
Optogenetic silencing to achieve antiarrhythmic effect of renal denervation in chronic heart failure$581,065
R01 · FY2025 · HL · contact PI
Neuromuscular junction as a therapeutic target to improve post-traumatic outcomes$376,075
R01 · FY2025 · GM · contact PI
Mechanisms of cardiac sympathetic hyperactivity in chronic heart failure$632,166
R01 · FY2024 · HL · contact PI
Potential mechanism underlying parasympathetic neuronal dysfunction in diabetes$603,326
R01 · FY2024 · HL · contact PI
Optogenetic silencing to achieve antiarrhythmic effect of renal denervation in chronic heart failure$569,442
R01 · FY2024 · HL · contact PI
Neuromuscular junction as a therapeutic target to improve post-traumatic outcomes$376,075
R01 · FY2024 · GM · contact PI
Mechanisms of cardiac sympathetic hyperactivity in chronic heart failure$658,442
R01 · FY2023 · HL · contact PI
Optogenetic silencing to achieve antiarrhythmic effect of renal denervation in chronic heart failure$594,440
R01 · FY2023 · HL · contact PI
Neuromuscular junction as a therapeutic target to improve post-traumatic outcomes$376,075
R01 · FY2023 · GM · contact PI
Neuromuscular junction as a therapeutic target to improve post-traumatic outcomes$376,075
R01 · FY2022 · GM · contact PI
Potential therapies to improve ventricular vagal function in type 2 diabetes$381,250
R01 · FY2021 · HL · contact PI
Potential therapies to improve ventricular vagal function in type 2 diabetes$381,250
R01 · FY2020 · HL · contact PI
Mechanisms of cardiac sympathetic hyperactivity in chronic heart failure$376,250
R01 · FY2020 · HL · contact PI
Potential therapies to improve ventricular vagal function in type 2 diabetes$381,250
R01 · FY2019 · HL · contact PI
Mechanisms of cardiac sympathetic hyperactivity in chronic heart failure$376,250
R01 · FY2019 · HL · contact PI
Potential therapies to improve ventricular vagal function in type 2 diabetes$381,250
R01 · FY2018 · HL · contact PI
Mechanisms of cardiac sympathetic hyperactivity in chronic heart failure$376,250
R01 · FY2018 · HL · contact PI
Mechanisms of cardiac sympathetic hyperactivity in chronic heart failure$376,250
R01 · FY2017 · HL · contact PI
Dysfunction of Baroreceptor Neurons in Heart Failure: Cellular and Molecular Mech$349,896
R01 · FY2013 · HL · contact PI
Dysfunction of Baroreceptor Neurons in Heart Failure: Cellular and Molecular Mech$367,538
R01 · FY2012 · HL · contact PI
Dysfunction of Baroreceptor Neurons in Heart Failure: Cellular and Molecular Mech$371,250
R01 · FY2011 · HL · contact PI
Dysfunction of Baroreceptor Neurons in Heart Failure: Cellular and Molecular Mech$371,250
R01 · FY2010 · HL · contact PI